Diagnostic evaluation of hereditary hemochromatosis (HFE and Non-HFE)

Hematology/Oncology Clinics of North America

Volumn 28, Issue 4, 2014, Pages 625-635

  Bardou Jacquet, Edouard ^a,b   Brissot, Pierre ^a,b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Ferroportin; Hemochromatosis; Hemojuvelin; Hepcidin; HFE; Phlebotomy; TFR2

Indexed keywords

FERROPORTIN; HEPCIDIN; IRON; TRANSFERRIN;

BONE; CAUCASIAN; FERROPORTIN DISEASE; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; HAMP RELATED HEMOCHROMATOSIS; HEART; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HFE RELATED HEMOCHROMATOSIS; HJV RELATED HEMOCHROMATOSIS; HUMAN; HYPOPHYSIS; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; JOINT; LIVER DISEASE; MEDICAL HISTORY; PANCREAS; PENETRANCE; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN DEFECT; REGULATORY MECHANISM; REVIEW; TFR2 RELATED HEMOCHROMATOSIS; GENETICS; METABOLISM;

GENETIC TESTING; HEMOCHROMATOSIS; HUMANS; IRON;

EID: 84904813362     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.04.006     Document Type: Review

References (40)

1. Gunshin H., Fujiwara Y., Custodio A.O., et al. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005, 115(5):1258-1266.
2. Donovan A., Brownlie A., Zhou Y., et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 403(6771):776-781.
3. Park C.H., Valore E.V., Waring A.J., et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276(11):7806-7810.
4. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276(11):7811-7819.
5. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001, 98(15):8780-8785.
6. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
7. Meynard D., Kautz L., Darnaud V., et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41(4):478-481.
8. Goswami T., Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006, 281(39):28494-28498.
9. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 2005, 105(10):4103-4105.
10. Bardou-Jacquet E., Philip J., Lorho R., et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 2014, 59(3):839-847.
11. Le Lan C., Loreal O., Cohen T., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005, 105(11):4527-4531.
12. De Domenico I., Ward D.M., Musci G., et al. Iron overload due to mutations in ferroportin. Haematologica 2006, 91(1):92-95.
13. Drakesmith H., Schimanski L.M., Ormerod E., et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005, 106(3):1092-1097.
14. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358(3):221-230.
15. Beutler E., Felitti V.J., Koziol J.A., et al. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359(9302):211-218.
16. EASL EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010, 53(1):3-22.
17. Moirand R., Adams P.C., Bicheler V., et al. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997, 127(2):105-110.
18. Loreal O., Deugnier Y., Moirand R., et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 1992, 16(1-2):122-127.
19. Desgrippes R., Laine F., Morcet J., et al. Decreased iron burden in overweight C282Y homozygous women: putative role of increased hepcidin production. Hepatology 2013, 57(5):1784-1792.
20. Milet J., Dehais V., Bourgain C., et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 2007, 81(4):799-807.
21. Stickel F., Buch S., Zoller H., et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet 2014, [Epub ahead of print].
22. Adams P.C., Reboussin D.M., Press R.D., et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007, 120(11):999.e1-999.e7.
23. Niederau C., Fischer R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110(4):1107-1119.
24. Beaton M., Guyader D., Deugnier Y., et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002, 36(3):673-678.
25. Crawford D.H., Murphy T.L., Ramm L.E., et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009, 49(2):418-425.
26. Guyader D., Jacquelinet C., Moirand R., et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998, 115(4):929-936.
27. Murphy C.J., Oudit G.Y. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 2010, 16(11):888-900.
28. Le Lan C., Mosser A., Ropert M., et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology 2011, 140(4):1199-1207.e1-2.
29. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
30. Walsh A., Dixon J.L., Ramm G.A., et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006, 4(11):1403-1410.
31. Aguilar-Martinez P., Grandchamp B., Cunat S., et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica 2011, 96(4):507-514.
32. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36(1):77-82.
33. Roetto A., Papanikolaou G., Politou M., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33(1):21-22.
34. Piperno A., Roetto A., Mariani R., et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004, 89(3):359-360.
35. Bardou-Jacquet E., Cunat S., Beaumont-Epinette M.P., et al. Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations. Br J Haematol 2013, 162(2):278-281.
36. Njajou O.T., Vaessen N., Joosse M., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001, 28(3):213-214.
37. Detivaud L., Island M.L., Jouanolle A.M., et al. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype. Hum Mutat 2013, 34(11):1529-1536.
38. Drakesmith H., Prentice A.M. Hepcidin and the iron-infection axis. Science 2012, 338(6108):768-772.
39. Miyajima H., Takahashi Y., Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003, 16(1):205-213.
40. Kautz L., Jung G., Nemeth E., et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood 2013, 122(21):4. [abstract].